HCW Biologics Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
HCW Biologics filed an 8-K on 2026-08-14 disclosing Item 4.02 (non-reliance on previously issued financial statements or audit report). No specific dollar amounts, affected periods, nature of restatement errors, or remedial actions are detailed in the filing header. The actual restatement narrative is not provided in the document excerpts available.
Why this rating
Restatement signals control/disclosure failures; material for $6.2M market-cap company. Lack of detail prevents full assessment; likely investor confidence erosion.
Extracted items
- 4.02 non-reliance / restatement
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.